Tilray® Inc., a global leader in cannabis research, production and distribution, announced today that Tilray 2:100, a product produced at Tilray’s federally licensed, Good Manufacturing Practice (GMP)-certified facility in Canada, was successfully imported into the United Kingdom, to supply a paediatric patient in need.
The changing regulatory measures in the UK previously prohibited the use of medical cannabis. However, in July 2018, Home Secretary Sajid Javid announced that clinicians will now legally be able to prescribe cannabis-derived medicines to patients with an exceptional clinical need noting “recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory”.
With government-approved compassionate access, the UK-based patient suffering from a rare form of epilepsy now has reliable
... read more at: https://www.healtheuropa.eu/tilray-cbd-oil/88056/